...
首页> 外文期刊>P & T: a peer-reviewed journal for formulary management >Irritable bowel syndrome: Current and emerging treatment options
【24h】

Irritable bowel syndrome: Current and emerging treatment options

机译:肠易激综合征:当前和新兴的治疗选择

获取原文
获取原文并翻译 | 示例

摘要

INTRODUCTION: Irritable bowel syndrome (IBS), one of the most prevalent functional gastrointestinal disorders, affects up to 55 million Americans, most of them women. IBS is a chronic disorder characterized by abdominal pain or discomfort associated with altered bowel function for at least three months, according to the Rome III criteria. Patients often experience relapse of symptoms over time. IBS symptoms cannot be explained by structural abnormalities, and IBS pathophysiology, which is thought to be multifactorial, is not well understood.
机译:简介:肠易激综合症(IBS)是最普遍的功能性胃肠道疾病之一,影响了多达5500万美国人,其中大多数是女性。根据罗马三世的标准,IBS是一种慢性疾病,其特征是至少三个月的腹痛或不适感与肠功能改变有关。随着时间的流逝,患者经常会出现症状复发。 IBS症状不能用结构异常来解释,IBS病理生理学(被认为是多因素的)还没有得到很好的理解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号